Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG:1349)
Hong Kong
· Delayed Price · Currency is HKD 2.760
+0.050 (1.85%)
Apr 29, 2026, 4:08 PM HKT
HKG:1349 Ratios and Metrics
Market cap in millions HKD. Fiscal year is January - December.
Millions HKD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Apr '26 Apr 28, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Market Capitalization | 7,121 | 7,469 | 6,602 | 8,057 | 7,767 | 13,434 | Upgrade
|
| Market Cap Growth | -0.30% | 13.14% | -18.06% | 3.73% | -42.18% | -14.60% | Upgrade
|
| Enterprise Value | 5,861 | 6,265 | 5,465 | 6,850 | 6,427 | 12,106 | Upgrade
|
| Last Close Price | 2.71 | 2.78 | 2.44 | 2.39 | 3.16 | 3.42 | Upgrade
|
| PE Ratio | - | - | 156.13 | 67.32 | 49.79 | 51.31 | Upgrade
|
| Forward PE | - | 22.46 | 22.46 | 22.46 | 22.46 | 22.46 | Upgrade
|
| PS Ratio | 9.33 | 9.79 | 8.74 | 8.60 | 6.66 | 9.60 | Upgrade
|
| PB Ratio | 3.02 | 3.17 | 2.69 | 3.10 | 3.05 | 5.00 | Upgrade
|
| P/TBV Ratio | 3.11 | 3.27 | 2.78 | 3.22 | 3.13 | 5.20 | Upgrade
|
| P/FCF Ratio | 58.69 | 61.56 | - | - | 88.13 | 73.56 | Upgrade
|
| P/OCF Ratio | 45.26 | 47.47 | - | 102.98 | 41.57 | 40.70 | Upgrade
|
| PEG Ratio | - | 0.69 | 0.69 | 0.69 | 0.69 | 0.69 | Upgrade
|
| EV/Sales Ratio | 7.68 | 8.21 | 7.24 | 7.31 | 5.51 | 8.65 | Upgrade
|
| EV/EBITDA Ratio | - | - | 87.73 | 48.18 | 30.41 | 45.55 | Upgrade
|
| EV/EBIT Ratio | - | - | - | 80.59 | 49.83 | 60.61 | Upgrade
|
| EV/FCF Ratio | 48.31 | 51.63 | - | - | 72.92 | 66.29 | Upgrade
|
| Debt / Equity Ratio | 0.01 | 0.01 | 0.01 | 0.01 | 0.06 | 0.01 | Upgrade
|
| Debt / EBITDA Ratio | - | - | 0.31 | 0.13 | 0.64 | 0.14 | Upgrade
|
| Debt / FCF Ratio | 0.14 | 0.14 | - | - | 1.60 | 0.21 | Upgrade
|
| Net Debt / Equity Ratio | -0.53 | -0.53 | -0.45 | -0.50 | -0.53 | -0.54 | Upgrade
|
| Net Debt / EBITDA Ratio | 10.80 | 10.80 | -17.70 | -9.13 | -6.39 | -5.44 | Upgrade
|
| Net Debt / FCF Ratio | -10.39 | -10.39 | 17.50 | 42.17 | -15.32 | -7.91 | Upgrade
|
| Asset Turnover | 0.28 | 0.28 | 0.26 | 0.29 | 0.36 | 0.43 | Upgrade
|
| Inventory Turnover | 1.76 | 1.76 | 1.40 | 1.76 | 2.27 | 2.26 | Upgrade
|
| Quick Ratio | 5.88 | 5.88 | 6.09 | 3.60 | 2.98 | 3.56 | Upgrade
|
| Current Ratio | 6.05 | 6.05 | 6.40 | 3.70 | 3.07 | 3.65 | Upgrade
|
| Return on Equity (ROE) | -7.13% | -7.13% | 1.69% | 4.70% | 6.18% | 10.12% | Upgrade
|
| Return on Assets (ROA) | -4.01% | -4.01% | -0.18% | 1.65% | 2.48% | 3.85% | Upgrade
|
| Return on Invested Capital (ROIC) | -14.94% | -14.19% | -0.63% | 6.89% | 11.02% | 19.48% | Upgrade
|
| Return on Capital Employed (ROCE) | -7.50% | -7.50% | -0.30% | 3.30% | 5.00% | 7.20% | Upgrade
|
| Earnings Yield | -2.46% | -2.35% | 0.64% | 1.49% | 2.01% | 1.95% | Upgrade
|
| FCF Yield | 1.70% | 1.62% | -0.95% | -0.38% | 1.14% | 1.36% | Upgrade
|
| Dividend Yield | 1.16% | - | 2.18% | 3.23% | 2.50% | 2.51% | Upgrade
|
| Payout Ratio | - | - | 234.79% | 70.10% | 51.48% | 24.45% | Upgrade
|
| Buyback Yield / Dilution | - | - | -0.23% | -0.29% | 1.29% | -5.59% | Upgrade
|
| Total Shareholder Return | 1.15% | - | 1.95% | 2.94% | 3.80% | -3.08% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.